C. Davite

发表

A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial

S. Barni, R. Labianca, L. Cavanna, 2022, Gastric Cancer.

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

R. Bosotti, A. Isacchi, A. Bardelli, 2015, Journal of the National Cancer Institute.

Treatment of chronic hepatitis C with recombinant human interferon‐α2a: Results of a randomized controlled clinical trial

M. Rugge, G. Realdi, A. Tagger, 1994 .

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

H. Dombret, H. Kantarjian, J. Cortes, 2015, Haematologica.

Preliminary Results of a Phase I/II Trial of BBR-2778 (Pixantrone) in Combination with Fludarabine, Dexamethasone, and Rituximab (FPD-R) in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

L. Fayad, G. Cohen, B. Pro, 2004 .

Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial.

M. Rugge, A. Tagger, F. Noventa, 1994, Hepatology.

Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients.

G. Giaccone, S. Novello, G. Weiss, 2018 .

A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC).

G. Giaccone, S. Novello, G. Weiss, 2014 .

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors

A. Isacchi, G. Weiss, F. Fiorentini, 2018, Investigational New Drugs.

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II

T. Gauler, A. Santoro, M. D. de Jonge, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML

R. Bosotti, A. Isacchi, L. Zanetta, 2019, Blood.

Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC).

E. Smit, S. Novello, T. Gauler, 2013 .